Overview

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.
Phase:
Phase 2
Details
Lead Sponsor:
GPCR Therapeutics, Inc.
TaiGen Biotechnology Co., Ltd.